GenCART is a privately held, clinical-stage biotechnology company based in Pittsburgh, PA, engineering next-generation CAR-T therapies for blood cancers and advancing research into autoimmune disorders (including SLE, RA, and MS). We are building a resilient, decentralized model to bring manufacturing closer to patients—shortening time to treatment, improving reliability, and expanding access.

Investment Highlights

• Compelling Mission & Model: Decentralized, patient-proximal manufacturing designed to reduce logistics bottlenecks and accelerate time-to-infusion.
• Clinical Momentum: Lead CD19 program in Phase 1; CD22 and dual CD19/CD22 programs in Pre-Clinical development.
• Broadened Impact: Initial focus on high-need lymphoma populations (first-line high-risk, relapsed, and post-CAR-T failure), with an expansion path into autoimmune diseases.
• Platform Innovation: Exploring virus-free and advanced delivery approaches aimed at improving safety, consistency, and scalability.
• Execution Ecosystem: Pittsburgh’s integrated med-tech and manufacturing base supports cost-effective development and multi-site deployment.

Collaboration & Capital

We welcome discussions with long-term partners who share our vision of making transformative cell therapies reliable, local, and equitable. Opportunities include equity financing, strategic partnerships, manufacturing collaborations, and site enablement.

Contact

If you would like to consider an investment or request additional materials (deck, data room access, or diligence packet), please contact us:

Email: Info@GenCARTbio.com